ATE521608T1 - Glucokinaseaktivatoren - Google Patents

Glucokinaseaktivatoren

Info

Publication number
ATE521608T1
ATE521608T1 AT06826456T AT06826456T ATE521608T1 AT E521608 T1 ATE521608 T1 AT E521608T1 AT 06826456 T AT06826456 T AT 06826456T AT 06826456 T AT06826456 T AT 06826456T AT E521608 T1 ATE521608 T1 AT E521608T1
Authority
AT
Austria
Prior art keywords
glucokinase
glucokinase activators
underactivity
diseases
prevention
Prior art date
Application number
AT06826456T
Other languages
English (en)
Inventor
Thomas Daniel Aicher
Wai-Man Lee
Ronald Jay Hinklin
Mark Joseph Chicarelli
Steven Armen Boyd
Kevin Ronald Condroski
Original Assignee
Array Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Array Biopharma Inc filed Critical Array Biopharma Inc
Application granted granted Critical
Publication of ATE521608T1 publication Critical patent/ATE521608T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
AT06826456T 2005-11-01 2006-10-24 Glucokinaseaktivatoren ATE521608T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US73203705P 2005-11-01 2005-11-01
PCT/US2006/041251 WO2007053345A1 (en) 2005-11-01 2006-10-24 Glucokinase activators

Publications (1)

Publication Number Publication Date
ATE521608T1 true ATE521608T1 (de) 2011-09-15

Family

ID=37685330

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06826456T ATE521608T1 (de) 2005-11-01 2006-10-24 Glucokinaseaktivatoren

Country Status (9)

Country Link
US (1) US8933077B2 (de)
EP (1) EP1948652B1 (de)
JP (1) JP5137207B2 (de)
AT (1) ATE521608T1 (de)
AU (1) AU2006309173B2 (de)
CA (1) CA2628274A1 (de)
ES (1) ES2372540T3 (de)
NZ (1) NZ567858A (de)
WO (1) WO2007053345A1 (de)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1785420A1 (de) * 2005-11-14 2007-05-16 4Sc Ag Thiazolanalogen und ihre Verwendung
CA2666193A1 (en) 2006-08-08 2008-02-14 Sanofi-Aventis Arylaminoaryl-alkyl-substituted imidazolidine-2,4-diones, process for preparing them, medicaments comprising these compounds, and their use
EP2173745A2 (de) * 2007-03-23 2010-04-14 Array Biopharma, Inc. 2-aminopyridinanaloga als glukokinaseaktivatoren
WO2009022179A2 (en) * 2007-08-14 2009-02-19 Astrazeneca Ab Glucokinase activators in the treatment of osteoarthritis
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
AU2008305294B2 (en) 2007-09-21 2012-11-29 Array Biopharma Inc. Pyridin-2 -yl-amino-1, 2, 4 -thiadiazole derivatives as glucokinase activators for the treatment of diabetes mellitus
ES2399469T3 (es) * 2007-10-09 2013-04-01 Merck Patent Gmbh Derivados de la piridina útiles como activadores de la glucoquinasa
CN101896483B (zh) 2007-12-20 2013-11-20 株式会社Lg生命科学 葡糖激酶激活剂和包含其作为活性成分的药物组合物
EP2310372B1 (de) 2008-07-09 2012-05-23 Sanofi Heterocyclische Verbindungen, Verfahren zu ihrer Herstellung, Arzneimitteln mit diesen Verbindungen und ihre Verwendung
WO2010068601A1 (en) 2008-12-08 2010-06-17 Sanofi-Aventis A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof
JP2012520845A (ja) * 2009-03-17 2012-09-10 グラクソ グループ リミテッド Ｉｔｋ阻害剤として使用されるピリミジン誘導体
CA2767476A1 (en) * 2009-07-10 2011-01-13 Bayer Pharma Aktiengesellschaft Indazolyl-substituted dihydroisoxazolopyridines and methods of use thereof
EP2470552B1 (de) 2009-08-26 2013-11-13 Sanofi Neuartige kristalline heteroaromatische Fluorglycosidhydrate, Pharmazeutika, die diese Verbindungen umfassen, und deren Verwendung
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2553086B1 (de) 2010-03-31 2017-04-19 The Scripps Research Institute Umprogrammierung von zellen
EP2582709B1 (de) 2010-06-18 2018-01-24 Sanofi Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
WO2012120052A1 (de) 2011-03-08 2012-09-13 Sanofi Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2683704B1 (de) 2011-03-08 2014-12-17 Sanofi Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2683705B1 (de) 2011-03-08 2015-04-22 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
US8871758B2 (en) 2011-03-08 2014-10-28 Sanofi Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
US8710050B2 (en) 2011-03-08 2014-04-29 Sanofi Di and tri- substituted oxathiazine derivatives, method for the production, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
TW201247649A (en) 2011-03-09 2012-12-01 Daiichi Sankyo Co Ltd Dipyridylamine derivative
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013045413A1 (en) 2011-09-27 2013-04-04 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
JP2015505536A (ja) * 2012-01-20 2015-02-23 アクセラ インク． 疾患の処置のための置換された複素環化合物
CA2877026A1 (en) 2012-05-18 2013-11-21 Amgen Inc. Method for the preparation of thiadiazoles
US11357759B2 (en) 2017-10-29 2022-06-14 China Medical University Composition including ADAM9 inhibitor and the use thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6596476B1 (en) * 1989-12-22 2003-07-22 Abbott Laboratories Hepatitis C assay
EP3222619A1 (de) 1999-04-15 2017-09-27 Bristol-Myers Squibb Holdings Ireland Cyclische proteintyrosinkinase-inhibitoren
US7125875B2 (en) * 1999-04-15 2006-10-24 Bristol-Myers Squibb Company Cyclic protein tyrosine kinase inhibitors
KR20020027635A (ko) * 1999-09-10 2002-04-13 폴락 돈나 엘. 티로신 키나제 억제제
EP1345922B1 (de) * 2000-12-21 2006-05-31 Vertex Pharmaceuticals Incorporated Pyrazolverbindungen als protein-kinase-inhibitoren
GB0226931D0 (en) * 2002-11-19 2002-12-24 Astrazeneca Ab Chemical compounds
UA82867C2 (en) * 2003-02-13 2008-05-26 Banyu Pharma Co Ltd 2-pyridinecarboxamide derivatives
JPWO2005090332A1 (ja) * 2004-03-23 2008-01-31 萬有製薬株式会社 置換キナゾリン又はピリドピリミジン誘導体

Also Published As

Publication number Publication date
CA2628274A1 (en) 2007-05-10
US8933077B2 (en) 2015-01-13
JP5137207B2 (ja) 2013-02-06
ES2372540T3 (es) 2012-01-23
JP2009513700A (ja) 2009-04-02
US20100056530A1 (en) 2010-03-04
EP1948652A1 (de) 2008-07-30
AU2006309173B2 (en) 2011-08-18
WO2007053345A1 (en) 2007-05-10
EP1948652B1 (de) 2011-08-24
AU2006309173A1 (en) 2007-05-10
NZ567858A (en) 2011-08-26

Similar Documents

Publication Publication Date Title
ATE521608T1 (de) Glucokinaseaktivatoren
SG170775A1 (en) 2 -aminopyridine analogs as glucokinase activators
TW200740804A (en) Glucokinase activators
WO2008118718A3 (en) 2-aminopyridine analogs as glucokinase activators
CR11383A (es) Derivados piridin-2-il-amino-1,2,4 -tiadiazol como activadores glucoquinasa para el tratamiento de la diabetes mellitus
NO20074943L (no) Roflumilast for behandlingen av diabetes mellitus
WO2006091459A3 (en) Compositions and methods for treating vascular permeability
TW200745037A (en) Organic compounds
ATE435015T1 (de) Substituierte benzazole und ihre verwendung als raf-kinase-hemmer
MX2007005590A (es) Compuestos del inhibidor glicogeno fosforilasa y sus composiciones farmaceuticas.
TW200608979A (en) Pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
MX2007007409A (es) Derivados de rapamicina y los usos de los mismos en el tratamiento de trastornos neurologicos.
EA201071089A1 (ru) Производные хиназолина как модуляторы raf-киназы и способы их применения
ATE480255T1 (de) Zusammensetzungen und verfahren zur kontrolle, prävention und behandlung von essstörungen
GB0402137D0 (en) Novel compounds
TNSN06315A1 (en) Sulfonamide-thiazolpyridine derivatives as glucokinase activators useful the treatment of type 2 diabetes
WO2010029089A3 (en) Combination therapy for the treatment of diabetes and related conditions
NO20092639L (no) 4-fenyl-6-(2,2,2-trifluor-1-fenyletoksy)pynmidinbaserte forbindelser og anvendelser derav
ATE552000T1 (de) Verwendung von isothiocyanat-verbindungen zur behandlung von prostata-erkrankungen und hautkrebs
TW200738724A (en) Substituted 4-amino-pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
TW200714604A (en) Substituted heterocycles and the uses thereof
MX2010010317A (es) Compuestos heterociclicos novedosos y usos de los mismos.
GB0402143D0 (en) Novel compounds
MX2007007781A (es) Composiciones cardiovasculares.
ATE542535T1 (de) Verwendung von azapaullonen zur vorbeugung und behandlung pankreatischer autoimmunkrankheiten

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties